SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-23-000088
Filing Date
2023-12-11
Accepted
2023-12-11 09:01:19
Documents
20
Period of Report
2023-12-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20231211.htm   iXBRL 8-K 27584
2 EX-99.1 ersatoplinepresentationf.htm EX-99.1 8875
6 ersatoplinepresentationf001.jpg GRAPHIC 62237
7 ersatoplinepresentationf002.jpg GRAPHIC 152072
8 ersatoplinepresentationf003.jpg GRAPHIC 117234
9 ersatoplinepresentationf004.jpg GRAPHIC 95081
10 ersatoplinepresentationf005.jpg GRAPHIC 87943
11 ersatoplinepresentationf006.jpg GRAPHIC 94093
12 ersatoplinepresentationf007.jpg GRAPHIC 65987
  Complete submission text file 0001819790-23-000088.txt   1099608

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20231211.xsd EX-101.SCH 1892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20231211_lab.xml EX-101.LAB 24833
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20231211_pre.xml EX-101.PRE 13037
14 EXTRACTED XBRL INSTANCE DOCUMENT tars-20231211_htm.xml XML 2929
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 231477034
SIC: 2836 Biological Products, (No Diagnostic Substances)